Trial Profile
Ascending Single-Dose Study of the Safety, Tolerability, and Pharmacokinetics of ERB-257 Administered Intravenously as a 30-Minute Infusion to Healthy Japanese Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 May 2014
Price :
$35
*
At a glance
- Drugs ERB 257 (Primary)
- Indications Sepsis
- Focus Adverse reactions
- Sponsors Wyeth
- 08 May 2014 New trial record